

CLAIMS

1. A salt of Formula IV:




Formula IV ,

said salt being a combination of a compound of Formula I and tartaric acid:



Formula I



Tartaric acid

in a ratio of 1:n,
wherein
n is 0.5 or 1.

2. The salt of Formula IV according to claim 1, wherein the tartaric acid is L-(+)-tartaric acid.

3. The salt of Formula IV according to claim 1, wherein the tartaric acid is D-(-)-tartaric acid.

4. The salt of Formula IV according to claim 1, wherein the tartaric acid is L-(+)-tartaric acid and D-(-)-tartaric acid.

.

5. The salt of Formula IV according to any one of the preceding claims, wherein n is 0.5.

6. The salt of Formula IV according to any one of claims 1-4, wherein n is 1.

7. The salt of Formula IV according to any one of the preceding claims, characterized by being crystalline.

8. The salt of Formula IV according to any one of claims 1-5 or 7, characterized by an XRP diffractogram as shown in Figure 1.

9. The salt of Formula IV according to any one of claims 1-5 or 7-8, characterized by an XRP diffractogram comprising a peak at 13.0 2θ and one or more peaks selected from the following: 12.4, 14.4, 21.1, 24.4 2θ.

10. A pharmaceutical composition comprising a salt of Formula IV according to any one of the preceding claims in admixture with a pharmaceutically acceptable excipient, carrier and/or diluent.

11. The pharmaceutical composition according to claim 10 comprising the compound of Formula I in an amount from 2.0 mg up to 10.0 mg.

12. The pharmaceutical composition according to claim 10 or 11, wherein the amount of the compound of Formula I is 2.5 mg, 5.0 mg or 7.5 mg.

13. The pharmaceutical composition according to claim 11 or 12, wherein the pharmaceutical composition is provided in a single dosage form.

14. The salt of Formula IV according to any one of claims 1-9 or the pharmaceutical composition according to any one of claims 10-13 for use as a medicament.

15. The salt according to any one of claims 1-9 or the pharmaceutical composition according to any one of claims 10-13 for use in the treatment and/or prevention of

a disease, disorder and/or condition selected from the group consisting of psychosis, schizophrenia, schizophreniform disorder, bipolar disorder, psychotic disorder, drug induced psychotic disorder, mood disorder, anxiety disorder, depression, obsessive-compulsive disease, dementia, age-related cognitive impairment, Autism spectrum disorders, ADHD, cerebral Palsy, Gilles de la Tourette's syndrome, brain injury, sleep disorder, sexual disorder, eating disorder, obesity, headache, pains in conditions characterized by increased muscular tone, Parkinson's disease, parkinsonian syndrome, dyskinesia, L-DOPA induced dyskinesias, Tardive dyskinesias, dystonia, tics and tremor dementia, Huntington's disease, movement disorder induced by drugs, restless legs, narcolepsy and, Alzheimer’s disease.

16. The salt or the pharmaceutical composition for use according to claim 15, wherein the disease, disorder and or condition is schizophrenia, L-DOPA induced dyskinesias and/or Huntington's disease.

17. The salt or the pharmaceutical composition for use according to claim 15 or 16, wherein the disease, disorder and/or condition is L-DOPA induced dyskinesias.

18. The salt or the pharmaceutical composition for use according to any one of claims 15-17, wherein the salt or the pharmaceutical composition is to be administered to a patient in a dosage from 2.0 mg up to 10.0 mg such as 2.5 mg, 5.0 mg or 7.5 mg.

19. The salt or the pharmaceutical composition for use according to claim 18, wherein the disease, disorder and/or condition, or
symptoms associated with said disease, disorder and/or condition
is/are alleviated and/or reduced to a greater extent as compared to administration of the salt or the pharmaceutical composition to a patient in a dosage equal to or greater than 10 mg

20. The salt or the pharmaceutical composition for use according to claim 19, wherein the administration of the dosage equal to or greater than 10 mg and the administration of the dosage from 2.0 up to 10.0 mg take place an equal number

of times such as an equal number of times daily.

21. Use of a salt according to any one of claims 1-9 or a pharmaceutical composition according to any one of claims 10-13 for the manufacture of a medicament for the treatment and/or prevention of a disease, disorder and/or condition selected from the group consisting of psychosis, schizophrenia, schizophreniform disorder, bipolar disorder, psychotic disorder, drug induced psychotic disorder, mood disorder, anxiety disorder, depression, obsessive-compulsive disease, dementia, age-related cognitive impairment, Autism spectrum disorders, ADHD, cerebral Palsy, Gilles de la Tourette's syndrome, brain injury, sleep disorder, sexual disorder, eating disorder, obesity, headache, pains in conditions characterized by increased muscular tone, Parkinson's disease, parkinsonian syndrome, dyskinesia, L-DOPA induced dyskinesias, Tardive dyskinesias, dystonia, tics and tremor dementia, Huntington's disease, movement disorder induced by drugs, restless legs, narcolepsy and, Alzheimer’s disease.

22. The use according to claim 21, wherein the disease, disorder and or condition is schizophrenia, L-DOPA induced dyskinesias and/or Huntington's disease.

23. The use according to claim 21 or 22, wherein the disease, disorder and/or condition is L-DOPA induced dyskinesias.

24. The use according to any one of claims 21-23, wherein the salt or the pharmaceutical composition is to be administered to a patient in a dosage from 2.0 mg up to 10.0 mg such as 2.5 mg, 5.0 mg or 7.5 mg.

25. The use according to claim 24, wherein
the disease, disorder and/or condition, or
symptoms associated with said disease, disorder and/or condition
is/are alleviated and/or reduced to a greater extent as compared to administration of the salt or the pharmaceutical composition to a patient in a dosage equal to or greater than 10 mg.

26. The use according to claim 25, wherein the administration of the dosage equal to or greater than 10 mg and the administration of the dosage from 2.0 mg up to 10.0

mg take place an equal number of times such as an equal number of times daily.

27. A method for preparing a salt of Formula IV according to any one of claims 1-9, said method comprising the steps of:
- providing a compound of Formula I and tartaric acid in a ratio of 1:0.5 or 1:1,
- combining said compound of Formula I with said tartaric acid in a solvent to form a solution, and
- allowing said solution to stand until a precipitate forms, and
- isolating said precipitate by filtration thereby providing the salt of Formula IV.

28. The method according to claim 27, wherein said solvent is a mixture of solvents.